{"entity":{"type":"insider","cik":"0001787456","url":"/insider/0001787456","json_url":"/insider/0001787456.json","name":"Longitude Venture Partners IV, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":5,"first":"2020-10-22","last":"2023-11-09","span_basis":"filed_date"},"name_variants":[{"name":"Longitude Venture Partners IV, L.P.","source":"filing","n_filings":5,"first_seen":"2020-10-22","last_seen":"2023-11-09"}],"transactions":[{"id":8296920,"accession":"0001209191-23-054904","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-054904","line_url":"/filing/0001209191-23-054904#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; Tammenoms Bakker Juliet; ENRIGHT PATRICK G","owner_display_name":"Longitude Capital Partners IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":2567100.0,"shares_owned_after_display":"2,567,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-07","filed_date":"2023-11-09","scope":"insider"},{"id":7799552,"accession":"0000899243-23-004349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-004349","line_url":"/filing/0000899243-23-004349#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Prime Fund, L.P.; Longitude Capital Partners IV, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners IV, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1714285.0,"shares_display":"1,714,285","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":11999995.0,"total_display":"11,999,995.00","total_whole":"11,999,995","shares_owned_after":1714285.0,"shares_owned_after_display":"1,714,285","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":6532421,"accession":"0000899243-22-013598","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-013598","line_url":"/filing/0000899243-22-013598#line-1","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":333333.0,"shares_display":"333,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":3429927.0,"shares_owned_after_display":"3,429,927","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-10","filed_date":"2022-04-05","scope":"insider"},{"id":5044196,"accession":"0001209191-21-033816","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-033816","line_url":"/filing/0001209191-21-033816#line-2","is_derivative":false,"issuer_cik":"0001431159","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001431159","owner_cik":null,"owner_name":"Longitude Venture Partners IV, L.P.; Longitude Capital Partners IV, LLC; Tammenoms Bakker Juliet","owner_display_name":"Longitude Venture Partners IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":3096594.0,"shares_owned_after_display":"3,096,594","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-18","filed_date":"2021-05-18","scope":"insider"},{"id":2732708,"accession":"0000899243-20-029109","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-029109","line_url":"/filing/0000899243-20-029109#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Eargo, Inc.","issuer_ticker":"EAR","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; ENRIGHT PATRICK G","owner_display_name":"Longitude Capital Partners IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":233333.0,"shares_display":"233,333","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":4199994.0,"total_display":"4,199,994.00","total_whole":"4,199,994","shares_owned_after":3918691.0,"shares_owned_after_display":"3,918,691","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-22","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001907108","name":"Lexeo Therapeutics, Inc.","url":"/issuer/0001907108","role":"Ten percent owner","n_filings":1,"first_seen":"2023-11-09","last_seen":"2023-11-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001831828","name":"Vera Therapeutics, Inc.","url":"/issuer/0001831828","role":"Ten percent owner","n_filings":3,"first_seen":"2021-05-18","last_seen":"2023-02-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001719395","name":"Eargo, Inc.","url":"/issuer/0001719395","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-22","last_seen":"2020-10-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001787456","retrieved_at":"2026-08-23T21:37:28+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}